To date, this is the first trial reporting on gradual changes in peripheral S100B levels in children and adolescents with ADHD receiving a triple therapy containing MPH and the anti-inflammatory combination of aMT and EPA/DHA. This evidence concerns the gene S100B and attention deficit-hyperactivity disorder.